Stockreport

Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

Chimerix, Inc.  (CMRX) 
Last chimerix, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.chimerix.com/investor-relations
PDF DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve [Read more]